Iryna A. Kostiuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iryna A. Kostiuk has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Kostyantyn Kosyachenko
Bogomolets National Medical University
3 shared publications - Anna Blagaia
Bogomolets National Medical University, Kyiv, Ukraine
1 shared publication - Dmytro Savchenko
Bogomolets National Medical University
1 shared publication - Iurii Kuchyn
Bogomolets National Medical University, Kyiv, Ukraine
1 shared publication K. L. Kosiachenko
1 shared publicationK. L. Kosyachenko
Bogomolets National Medical University, Kуiv
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 5 (63),p. 31-38
Implementation of the managed entry agreement framework in Ukraine: a national analysis of the pathway from health technology assessment to concluded agreements
The aim: to conduct a comprehensive analysis of the implementation of the Managed Entry Agreement (MEA) framework in the public procurement of medicines in Ukraine and to identify the main trends in its development. Materials and methods: a retrospective descriptive study was conducted using official, publicly available national data from the Medical Procurement of Ukraine and the State Expert Center of the Ministry of Health of Ukraine. During the study, a unified database was created that includes medicines under consideration for MEAs as of July 2026. The analysis covered 58 indications corresponding to 48 international non-proprietary names. Methods of content analysis, classification, structural analysis, comparative analysis and summarizing analysis were applied. Data analysis was conducted using descriptive statistics. Results: oncology accounted for the largest share of indications considered for MEAs (31; 53.4%), followed by immunological and other systemic diseases (17; 29.3%) and rare and genetic diseases (10; 17.2%). All included medicines underwent the national Health Technology Assessment (HTA) procedure and received approval to begin negotiations. As of July 2026, MEAs had been signed for 23 indications (39.7%), a negative decision had been recorded for 1 indication (1.7%), and no final decision on conducting an MEA had been recorded for 34 indications (58.6%). Roche had the largest therapeutic portfolio (13 indications), while Takeda and Pfizer were represented in all three therapeutic areas. The number of national HTA recommendations supporting MEA consideration increased from 6 in 2021 to 21 in 2025, indicating a gradual expansion of the MEA framework in Ukraine. Conclusions: the MEA framework is gradually being integrated into the mechanism for public financing of high-cost innovative medicines in Ukraine. National HTA is a key prerequisite for selecting medicines subject to the MEA. For 34 indications (58.6%), no final decision on conducting an MEA had been recorded as of July 2026. The findings provide the first systematic data on the implementation of the Ukrainian MEA framework and may contribute to the further optimization of negotiation procedures, policy development, and improved patient access to innovative medicines
- 30 October 2026
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 5 (63),p. 31-38
Open AccessImplementation of the managed entry agreement framework in Ukraine: a national analysis of the pathway from health technology assessment to concluded agreements
The aim: to conduct a comprehensive analysis of the implementation of the Managed Entry Agreement (MEA) framework in the public procurement of medicines in Ukraine and to identify the main trends in its development. Materials and methods: a retrospective descriptive study was conducted using official, publicly available national data from the Medical Procurement of Ukraine and the State Expert Center of the Ministry of Health of Ukraine. During the study, a unified database was created that includes medicines under consideration for MEAs as of July 2026. The analysis covered 58 indications corresponding to 48 international non-proprietary names. Methods of content analysis, classification, structural analysis, comparative analysis and summarizing analysis were applied. Data analysis was conducted using descriptive statistics. Results: oncology accounted for the largest share of indications considered for MEAs (31; 53.4%), followed by immunological and other systemic diseases (17; 29.3%) and rare and genetic diseases (10; 17.2%). All included medicines underwent the national Health Technology Assessment (HTA) procedure and received approval to begin negotiations. As of July 2026, MEAs had been signed for 23 indications (39.7%), a negative decision had been recorded for 1 indication (1.7%), and no final decision on conducting an MEA had been recorded for 34 indications (58.6%). Roche had the largest therapeutic portfolio (13 indications), while Takeda and Pfizer were represented in all three therapeutic areas. The number of national HTA recommendations supporting MEA consideration increased from 6 in 2021 to 21 in 2025, indicating a gradual expansion of the MEA framework in Ukraine. Conclusions: the MEA framework is gradually being integrated into the mechanism for public financing of high-cost innovative medicines in Ukraine. National HTA is a key prerequisite for selecting medicines subject to the MEA. For 34 indications (58.6%), no final decision on conducting an MEA had been recorded as of July 2026. The findings provide the first systematic data on the implementation of the Ukrainian MEA framework and may contribute to the further optimization of negotiation procedures, policy development, and improved patient access to innovative medicines
- Open Access
- 26 October 2026
- Published by Korea Health Personnel Licensing Examination Institute in Journal of Educational Evaluation for Health Professions
- Vol. 23, 33
Validity and fairness of Ukraine’s Krok examinations in the national medical qualification system during war
- 26 October 2026
- Published by Korea Health Personnel Licensing Examination Institute in Journal of Educational Evaluation for Health Professions
- Vol. 23, 33
Open AccessValidity and fairness of Ukraine’s Krok examinations in the national medical qualification system during war
- Open Access
- 13 October 2026
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 12 (3) , 15-26
The patient organizations’ involvement in the deliberative process of the health technology assessment: the international experience, current state and development prospects in Ukraine
The current development of health technology assessment (HTA) is characterized by a transition towards patient-centered decision-making models that provide for the systematic involvement of patient organizations in the deliberative process. Aim. To study the role of patient organizations in the deliberative HTA process, summarize their involvement practices across selected leading HTA agencies, and substantiate the prospects for developing relevant mechanisms in Ukraine. Materials and methods. Ukrainian regulatory acts in the field of HTA, international recommendations of HTAi, EUnetHTA and EUPATI, documents of leading HTA agencies (NICE, KCE, INESSS, HAS, SMC, HTW), scientific publications and open information resources were used. The content analysis, comparative, structural-logical and graphical methods, as well as generalization, were applied. Results and discussion. Modern approaches to involving patient organizations in the deliberative HTA process have been studied in accordance with the concept of Evidence-Informed Deliberative Processes. The patient involvement tools used by EUnetHTA, as well as interaction models implemented by leading international HTA agencies, have been analyzed. It has been found that in most countries, patient organizations are integrated into almost all stages of HTA – from prioritization to the development of recommendations on health technologies. The current development of the national HTA in Ukraine has been characterized, including the mainly consultative nature of patient organizations’ participation and the need to further develop mechanisms for their integration into the decision-making process. Based on the generalization of the international experience, a conceptual model for integrating patient organizations into the deliberative process of the state HTA in Ukraine has been developed, and promising areas for its further development have been identified. Conclusions. It has been determined that the international practice demonstrates a high level of institutionalization of the patient organizations’ participation in the HTA process, while in Ukraine their involvement remains mainly consultative. The model proposed can be used as a conceptual basis for improving the regulatory, organizational and methodological support of the state HTA.
- 13 October 2026
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 12 (3) , 15-26
Open AccessThe patient organizations’ involvement in the deliberative process of the health technology assessment: the international experience, current state and development prospects in Ukraine
The current development of health technology assessment (HTA) is characterized by a transition towards patient-centered decision-making models that provide for the systematic involvement of patient organizations in the deliberative process. Aim. To study the role of patient organizations in the deliberative HTA process, summarize their involvement practices across selected leading HTA agencies, and substantiate the prospects for developing relevant mechanisms in Ukraine. Materials and methods. Ukrainian regulatory acts in the field of HTA, international recommendations of HTAi, EUnetHTA and EUPATI, documents of leading HTA agencies (NICE, KCE, INESSS, HAS, SMC, HTW), scientific publications and open information resources were used. The content analysis, comparative, structural-logical and graphical methods, as well as generalization, were applied. Results and discussion. Modern approaches to involving patient organizations in the deliberative HTA process have been studied in accordance with the concept of Evidence-Informed Deliberative Processes. The patient involvement tools used by EUnetHTA, as well as interaction models implemented by leading international HTA agencies, have been analyzed. It has been found that in most countries, patient organizations are integrated into almost all stages of HTA – from prioritization to the development of recommendations on health technologies. The current development of the national HTA in Ukraine has been characterized, including the mainly consultative nature of patient organizations’ participation and the need to further develop mechanisms for their integration into the decision-making process. Based on the generalization of the international experience, a conceptual model for integrating patient organizations into the deliberative process of the state HTA in Ukraine has been developed, and promising areas for its further development have been identified. Conclusions. It has been determined that the international practice demonstrates a high level of institutionalization of the patient organizations’ participation in the HTA process, while in Ukraine their involvement remains mainly consultative. The model proposed can be used as a conceptual basis for improving the regulatory, organizational and methodological support of the state HTA.
- Open Access
- 28 August 2026
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 45-55
Integration of artificial intelligence into health technology assessment: optimizing clinical analysis and synthesis of evidence on effectiveness and safety
Clinical assessment is one of the most labor-intensive components of Health Technology Assessment, as it requires systematic literature retrieval, critical appraisal, and synthesis of scientific evidence. Recent advances in artificial intelligence have created new opportunities to optimize these processes; however, comparative analyses of artificial intelligence-based tools supporting the clinical component of Health Technology Assessment remain limited. The aim of the study was to systematize current evidence on the application of artificial intelligence in the clinical component of Health Technology Assessment and to identify its advantages, limitations, and prospects for evidence synthesis. The study was based on a structured review of scientific publications using descriptive, comparative, and content analysis methods. The findings demonstrated that contemporary artificial intelligence-based tools support different stages of evidence synthesis, including literature retrieval, publication screening, structured data extraction, risk-of-bias assessment, and evidence synthesis. According to their functional purpose, the identified tools were grouped into two principal categories: specialized platforms developed to automate specific stages of clinical assessment and large language models capable of supporting a broad range of analytical tasks. Comparative analysis revealed substantial differences in their functional capabilities, degree of automation, and potential applicability to Health Technology Assessment. None of the identified artificial intelligence-based tools currently supports the complete clinical assessment workflow, indicating that they should be regarded as complementary rather than interchangeable technologies. For Ukraine, the integration of artificial intelligence-based tools into national and hospital-based Health Technology Assessment offers promising opportunities to improve the efficiency of evidence synthesis, optimize the use of expert resources, and reduce the time required to prepare the clinical component of Health Technology Assessment reports. The implementation of artificial intelligence-based tools should be accompanied by mandatory expert validation of the obtained results. Further integration of artificial intelligence into Health Technology Assessment practice requires the development of methodological guidance together with clear principles governing the application and validation of artificial intelligence-based tools.
- 28 August 2026
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 45-55
Open AccessIntegration of artificial intelligence into health technology assessment: optimizing clinical analysis and synthesis of evidence on effectiveness and safety
Clinical assessment is one of the most labor-intensive components of Health Technology Assessment, as it requires systematic literature retrieval, critical appraisal, and synthesis of scientific evidence. Recent advances in artificial intelligence have created new opportunities to optimize these processes; however, comparative analyses of artificial intelligence-based tools supporting the clinical component of Health Technology Assessment remain limited. The aim of the study was to systematize current evidence on the application of artificial intelligence in the clinical component of Health Technology Assessment and to identify its advantages, limitations, and prospects for evidence synthesis. The study was based on a structured review of scientific publications using descriptive, comparative, and content analysis methods. The findings demonstrated that contemporary artificial intelligence-based tools support different stages of evidence synthesis, including literature retrieval, publication screening, structured data extraction, risk-of-bias assessment, and evidence synthesis. According to their functional purpose, the identified tools were grouped into two principal categories: specialized platforms developed to automate specific stages of clinical assessment and large language models capable of supporting a broad range of analytical tasks. Comparative analysis revealed substantial differences in their functional capabilities, degree of automation, and potential applicability to Health Technology Assessment. None of the identified artificial intelligence-based tools currently supports the complete clinical assessment workflow, indicating that they should be regarded as complementary rather than interchangeable technologies. For Ukraine, the integration of artificial intelligence-based tools into national and hospital-based Health Technology Assessment offers promising opportunities to improve the efficiency of evidence synthesis, optimize the use of expert resources, and reduce the time required to prepare the clinical component of Health Technology Assessment reports. The implementation of artificial intelligence-based tools should be accompanied by mandatory expert validation of the obtained results. Further integration of artificial intelligence into Health Technology Assessment practice requires the development of methodological guidance together with clear principles governing the application and validation of artificial intelligence-based tools.
- Open Access
- 13 August 2026
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 5,p. 140-146
THE ROLE OF EMOTIONAL INTELLIGENCE IN PREPARING MEDICAL PROFESSIONALS TO WORK WITH POST-TRAUMATIC STRESS DISORDER
Introduction. The growing burden of post-traumatic stress disorder (PTSD) in conflict-affected societies has intensified demands on healthcare systems and placed new pressures on the professional preparation of medical personnel. Among the competencies increasingly recognized as essential for effective trauma-focused clinical work, emotional intelligence (EI) occupies a central yet systematically underutilized position in contemporary medical education.Aim. To examine the role of EI in the professional preparation of medical specialists for clinical work with patients diagnosed with PTSD and to propose evidence-based recommendations for integrating EI-focused training into medical education curricula.Materials and methods. A mixed-methods study involving 124 medical professionals from clinical institutions and medical higher education establishments in Ukraine. EI was assessed using the Schutte Self-Report Emotional Intelligence Test (SSEIT), professional readiness was measured with Professional Readiness Scale (PRS-PTSD), burnout and compassion fatigue were evaluated using the ProQOL-5 scale. Quantitative data were analyzed with IBM SPSS Statistics v.26.0; qualitative data underwent reflexive thematic analysis. A subgroup of 42 participants completed a four-week EI development training program with pre- and post-training assessment.Results. Significant positive correlations were identified between total SSEIT scores and all three PRS-PTSD subscales (p < 0.05). Clinicians with higher EI demonstrated greater cognitive, emotional, and communicative readiness for PTSD care. Participants in the EI training program showed significant improvements in SSEIT scores and PRS-PTSD subscales post-intervention. Qualitative analysis revealed four major themes: emotional regulation under clinical pressure, barriers to empathic engagement, professional identity and resilience, and perceived gaps in EI-focused education.Conclusions. EI is a trainable and measurable professional competency directly linked to PTSD care readiness. Systematic integration of EI development into undergraduate and postgraduate medical curricula is strongly warranted. A multimodal, longitudinal approach combining reflective practice, simulation, and trauma-informed communication training is recommended.
- 13 August 2026
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 5,p. 140-146
Open AccessTHE ROLE OF EMOTIONAL INTELLIGENCE IN PREPARING MEDICAL PROFESSIONALS TO WORK WITH POST-TRAUMATIC STRESS DISORDER
Introduction. The growing burden of post-traumatic stress disorder (PTSD) in conflict-affected societies has intensified demands on healthcare systems and placed new pressures on the professional preparation of medical personnel. Among the competencies increasingly recognized as essential for effective trauma-focused clinical work, emotional intelligence (EI) occupies a central yet systematically underutilized position in contemporary medical education.Aim. To examine the role of EI in the professional preparation of medical specialists for clinical work with patients diagnosed with PTSD and to propose evidence-based recommendations for integrating EI-focused training into medical education curricula.Materials and methods. A mixed-methods study involving 124 medical professionals from clinical institutions and medical higher education establishments in Ukraine. EI was assessed using the Schutte Self-Report Emotional Intelligence Test (SSEIT), professional readiness was measured with Professional Readiness Scale (PRS-PTSD), burnout and compassion fatigue were evaluated using the ProQOL-5 scale. Quantitative data were analyzed with IBM SPSS Statistics v.26.0; qualitative data underwent reflexive thematic analysis. A subgroup of 42 participants completed a four-week EI development training program with pre- and post-training assessment.Results. Significant positive correlations were identified between total SSEIT scores and all three PRS-PTSD subscales (p < 0.05). Clinicians with higher EI demonstrated greater cognitive, emotional, and communicative readiness for PTSD care. Participants in the EI training program showed significant improvements in SSEIT scores and PRS-PTSD subscales post-intervention. Qualitative analysis revealed four major themes: emotional regulation under clinical pressure, barriers to empathic engagement, professional identity and resilience, and perceived gaps in EI-focused education.Conclusions. EI is a trainable and measurable professional competency directly linked to PTSD care readiness. Systematic integration of EI development into undergraduate and postgraduate medical curricula is strongly warranted. A multimodal, longitudinal approach combining reflective practice, simulation, and trauma-informed communication training is recommended.
- Open Access
- 30 March 2026
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 22 (1) , 145-152
HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT AS A TIOL FOR MANAGERIAL DECISION-MAKING: METHOLODOLOGICAL ANALYSIS
Background. The modern healthcare system requires effective mechanisms for health technology assessment (HTA) at the level of healthcare institutions (HCI) to ensure evidence-based implementation of innovations, optimize resources, and improve the quality of medical care. The absence of a systematic approach to hospital-based HTA ,ay lead to inefficient resource utilization, unjustified managerial decisions, and increased risks for patients, Aim: to summarize and scientifically substantiate approaches to implementing hospital-based HTA through the development of a structure HTA algorithm to support managerial regarding the adoption or withdrawal of medical technologies (MT) in healthcare institutions. Materials and methods. The study employed analysis and synthesis to generalize international and experience in HTA implementation, content analysis of legislative and regulatory documents, and systematization of approaches to hospital-based HTA. The information base included publications from PubMed and Cochrane Library, recommendations from international organization (EUnetHTA, AdHopHTA, DACENTA), and materials from pilot projects on hospital-based HTA in Ukraine. Results. A structured algorithm for hospital-based HTA was developed, comprising five key stages, defining the roles of a multidisciplinary team, and integration tools for assessing the clinical, economic, organizational, and strategic effectiveness of MT. The proposed approach ensures process transparency, supports evidence-based decision-making, optimizes resource allocation, and enables short- and long-term financial impact forecasting. Conclusions. The application of a comprehensive hospital-based HTA approach allows healthcare institutions to make informed managerial decisions regarding the adoption or withdraw of MT, reduced the risks of unjustified decisions, promotes innovation within HCIs, and increases stakeholder trust.
- 30 March 2026
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 22 (1) , 145-152
Open AccessHOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT AS A TIOL FOR MANAGERIAL DECISION-MAKING: METHOLODOLOGICAL ANALYSIS
Background. The modern healthcare system requires effective mechanisms for health technology assessment (HTA) at the level of healthcare institutions (HCI) to ensure evidence-based implementation of innovations, optimize resources, and improve the quality of medical care. The absence of a systematic approach to hospital-based HTA ,ay lead to inefficient resource utilization, unjustified managerial decisions, and increased risks for patients, Aim: to summarize and scientifically substantiate approaches to implementing hospital-based HTA through the development of a structure HTA algorithm to support managerial regarding the adoption or withdrawal of medical technologies (MT) in healthcare institutions. Materials and methods. The study employed analysis and synthesis to generalize international and experience in HTA implementation, content analysis of legislative and regulatory documents, and systematization of approaches to hospital-based HTA. The information base included publications from PubMed and Cochrane Library, recommendations from international organization (EUnetHTA, AdHopHTA, DACENTA), and materials from pilot projects on hospital-based HTA in Ukraine. Results. A structured algorithm for hospital-based HTA was developed, comprising five key stages, defining the roles of a multidisciplinary team, and integration tools for assessing the clinical, economic, organizational, and strategic effectiveness of MT. The proposed approach ensures process transparency, supports evidence-based decision-making, optimizes resource allocation, and enables short- and long-term financial impact forecasting. Conclusions. The application of a comprehensive hospital-based HTA approach allows healthcare institutions to make informed managerial decisions regarding the adoption or withdraw of MT, reduced the risks of unjustified decisions, promotes innovation within HCIs, and increases stakeholder trust.
- Open Access
- 26 June 2025
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 3,p. 48-57
Methodology for preparing a student project within the course «Health Technology Assessment» for second (masterʼs) level students in speciality I8 Pharmacy
The article substantiates the relevance of integrating a project-based approach into the study of the discipline Health Technology Assessment (HTA) in the training of second-level (master’s) students majoring in І8 Pharmacy. This approach contributes not only to the acquisition of knowledge but also to the development of critical thinking, analytical skills, the ability to work with evidence-based data, and to make well-founded managerial decisions. Given the increasing relevance of implementing evidence-based and economically sound decisions in the healthcare system, especially under conditions of limited resources, HTA is gaining importance as a tool for shaping transparent and rational management decisions. The rapid development of novel medical technologies, the emergence of innovative medicinal products, medical devices, and digital solutions require professionals to be capable of conducting systematic, objective, and context-adapted assessments. At the same time, Ukraine continues to experience a shortage of specialists qualified to apply HTA methodologies in their professional practice, which highlights the need to improve educational programs for pharmaceutical training. The aim of the study was to develop an educational and methodological framework for organizing a student project within the HTA discipline, focused on building professional competencies among students in the field of Pharmacy, in line with modern educational approaches and the current demands of pharmaceutical training. The result of the study is a structured model of a student project that includes five key stages, implemented through ten sequential steps. For each stage, appropriate tools, data sources, and recommended timeframes were identified. The proposed algorithm aligns with the stages outlined in the National Guideline for Health Technology Assessment of Medicinal Products in Ukraine, ensuring the standardization of approaches and enhancing the quality of the educational process. The developed educational toolkit enables an effective combination of theoretical training and practical work, simulating real-life professional scenarios relevant to future roles within the healthcare system. This approach not only improves the quality of student training but also fosters readiness for interdisciplinary collaboration and professional integration into the health sector.
- 26 June 2025
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 3,p. 48-57
Open AccessMethodology for preparing a student project within the course «Health Technology Assessment» for second (masterʼs) level students in speciality I8 Pharmacy
The article substantiates the relevance of integrating a project-based approach into the study of the discipline Health Technology Assessment (HTA) in the training of second-level (master’s) students majoring in І8 Pharmacy. This approach contributes not only to the acquisition of knowledge but also to the development of critical thinking, analytical skills, the ability to work with evidence-based data, and to make well-founded managerial decisions. Given the increasing relevance of implementing evidence-based and economically sound decisions in the healthcare system, especially under conditions of limited resources, HTA is gaining importance as a tool for shaping transparent and rational management decisions. The rapid development of novel medical technologies, the emergence of innovative medicinal products, medical devices, and digital solutions require professionals to be capable of conducting systematic, objective, and context-adapted assessments. At the same time, Ukraine continues to experience a shortage of specialists qualified to apply HTA methodologies in their professional practice, which highlights the need to improve educational programs for pharmaceutical training. The aim of the study was to develop an educational and methodological framework for organizing a student project within the HTA discipline, focused on building professional competencies among students in the field of Pharmacy, in line with modern educational approaches and the current demands of pharmaceutical training. The result of the study is a structured model of a student project that includes five key stages, implemented through ten sequential steps. For each stage, appropriate tools, data sources, and recommended timeframes were identified. The proposed algorithm aligns with the stages outlined in the National Guideline for Health Technology Assessment of Medicinal Products in Ukraine, ensuring the standardization of approaches and enhancing the quality of the educational process. The developed educational toolkit enables an effective combination of theoretical training and practical work, simulating real-life professional scenarios relevant to future roles within the healthcare system. This approach not only improves the quality of student training but also fosters readiness for interdisciplinary collaboration and professional integration into the health sector.
- Open Access
- 31 March 2025
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 21 (1) , 167-176
STUDY OF MOBILE APPLICATIONS OF PHARMACY CHAINS: UKRAINIAN AND INTERNATIONAL CONTEXT
Background. Ukraine has chosen digital transformation as one of its priority areas of development, which has already yielded significant results. The pharmaceutical industry as a component of the healthcare system is also in a state of constant transformation. Aim: to conduct a content analysis of mobile applications of domestic and foreign pharmacy chains. Materials and methods. The study was based on mobile applications of pharmacy chains. The following methods were used to conduct the study: literature review, content analysis, systemic, structural, logical and semantic analysis, graphical methods and generalization. Results and discussion. A content analysis of mobile applications of foreign pharmacy chains, in particular Apotheke (Germany), Wallgreens (USA), Wellcare Pharmacy (Qatar), was carried out. The structure and features of the interface of each of these applications are studied. With regard to the pharmacy market of Ukraine, it is established that there are five mobile applications in the country owned by companies that unite 12 brands of pharmacy chains. The user profile interface, the way of presenting the nomenclature of pharmacy assortment goods, as well as the functionality of loyalty programs in these applications are analyzed.
- 31 March 2025
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 21 (1) , 167-176
Open AccessSTUDY OF MOBILE APPLICATIONS OF PHARMACY CHAINS: UKRAINIAN AND INTERNATIONAL CONTEXT
Background. Ukraine has chosen digital transformation as one of its priority areas of development, which has already yielded significant results. The pharmaceutical industry as a component of the healthcare system is also in a state of constant transformation. Aim: to conduct a content analysis of mobile applications of domestic and foreign pharmacy chains. Materials and methods. The study was based on mobile applications of pharmacy chains. The following methods were used to conduct the study: literature review, content analysis, systemic, structural, logical and semantic analysis, graphical methods and generalization. Results and discussion. A content analysis of mobile applications of foreign pharmacy chains, in particular Apotheke (Germany), Wallgreens (USA), Wellcare Pharmacy (Qatar), was carried out. The structure and features of the interface of each of these applications are studied. With regard to the pharmacy market of Ukraine, it is established that there are five mobile applications in the country owned by companies that unite 12 brands of pharmacy chains. The user profile interface, the way of presenting the nomenclature of pharmacy assortment goods, as well as the functionality of loyalty programs in these applications are analyzed.
- Open Access
- 24 June 2024
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 3,p. 25-37
Analysis of the dynamics of the nomenclature of medicines for the treatment of mental and behavioral disorders in the government program «Affordable Medicines»
The number of patients with mental and behavioral disorders is growing rapidly in many countries around the world. Ukraine is not exception. The consequences of a full-scale war will cause severe mental trauma, as every 10th resident of our country now experiences depression, anxiety, and psychosomatic disorders that can last up to 10 years. All of this demonstrate the incredible relevance of comprehensive research to counteract the rapid increase in the incidence of mental and behavioral disorders, to find tools for effective treatment of this group of nosologies, and to find ways to improve the quality of life of patients. The aim of the study was to analyze the dynamics of the nomenclature of medicines for the treatment of mental and behavioral disorders in the Government Program «Affordable Medicines» for 2021–2024. To achieve this goal, we applied content analysis of regulatory legal acts using market research, as well as methods of comparative, statistical and economic analysis, as well as systematization and generalization. The results of the content analysis of all editions of the List of Medicinal Products Subject to Reimbursement under the State Guarantees for Medical Care of the Population revealed a stabilization of the number of international generic and brand names presented in the Government Program «Affordable Medicines» (9 and 65 respectively). However, given the martial law situation in Ukraine, the nomenclature of this group of drugs needs to be expanded. It was found that the range of medicinal products under study is dominated by domestically manufactured drugs, their segment is 54.5%, formed by 11 Ukrainian pharmaceutical companies. The foreign share is represented by 9 manufacturing countries, the most represented among which is India (16.9%). The number of medicinal products with full and partial reimbursement was analyzed and it was found that each of the international generic names under study has at least 1 product subject to full reimbursement. However, it is necessary to increase the number of medicines that are dispensed to patients free of charge for each international generic name, as a significant number of Ukrainians have mental and behavioral disorders and need greater economic accessibility to this particular group of drugs under martial law.
- 24 June 2024
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 3,p. 25-37
Open AccessAnalysis of the dynamics of the nomenclature of medicines for the treatment of mental and behavioral disorders in the government program «Affordable Medicines»
The number of patients with mental and behavioral disorders is growing rapidly in many countries around the world. Ukraine is not exception. The consequences of a full-scale war will cause severe mental trauma, as every 10th resident of our country now experiences depression, anxiety, and psychosomatic disorders that can last up to 10 years. All of this demonstrate the incredible relevance of comprehensive research to counteract the rapid increase in the incidence of mental and behavioral disorders, to find tools for effective treatment of this group of nosologies, and to find ways to improve the quality of life of patients. The aim of the study was to analyze the dynamics of the nomenclature of medicines for the treatment of mental and behavioral disorders in the Government Program «Affordable Medicines» for 2021–2024. To achieve this goal, we applied content analysis of regulatory legal acts using market research, as well as methods of comparative, statistical and economic analysis, as well as systematization and generalization. The results of the content analysis of all editions of the List of Medicinal Products Subject to Reimbursement under the State Guarantees for Medical Care of the Population revealed a stabilization of the number of international generic and brand names presented in the Government Program «Affordable Medicines» (9 and 65 respectively). However, given the martial law situation in Ukraine, the nomenclature of this group of drugs needs to be expanded. It was found that the range of medicinal products under study is dominated by domestically manufactured drugs, their segment is 54.5%, formed by 11 Ukrainian pharmaceutical companies. The foreign share is represented by 9 manufacturing countries, the most represented among which is India (16.9%). The number of medicinal products with full and partial reimbursement was analyzed and it was found that each of the international generic names under study has at least 1 product subject to full reimbursement. However, it is necessary to increase the number of medicines that are dispensed to patients free of charge for each international generic name, as a significant number of Ukrainians have mental and behavioral disorders and need greater economic accessibility to this particular group of drugs under martial law.
- Open Access
- 24 August 2023
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 62-79
Pharmacoeconomic analysis of the use of combinations of complex electrolyte compounds with citicoline in the treatment of patients with acute ischemic stroke in Ukraine
Ischemic stroke is a clinical syndrome of rapid development of signs of focal or global loss of brain function that lasts 24 hours or more or leads to death without other (nonvascular) causes. Cerebral stroke is one of the most severe forms of cerebrovascular disease. A significant place in stroke pharmacotherapy is occupied by prescription drugs that increase the preservation of nervous tissue. Citicoline is an essential mediator in phosphatidylcholine biosynthesis, a major component of biological membranes. The study aimed to analyze the cost-effectiveness and budget impact on using of complex electrolyt compounds with citicoline combinations in treatment of patients with acute ischemic stroke in Ukraine. The cost analysis was based on a decision tree model developed for treatment within 28 days after an ischemic stroke, including the likelihood that a patient will need to undergo rehabilitation care in an out-patient or in-patient treatment. The cost of direct expenses was determined based on the results of the course of Neurocytin® in combination with standard therapy, compared to the use of standard therapy alone, which, according to the results of the modelled analysis, is 30 407.10 UAH and 28 171.43 UAH per 1 person, respectively. Due to performing a pharmacoeconomic analysis using the cost-effectiveness method, the cost-utility indicator was calculated, which for treatment with Neurocytin® is 47 142.79 UAH, and for standard therapy – 46 031.74 UAH. The calculated ICUR value is 68 996.36 UAH, which indicates that the technology of Neurocytin® in combination with standard therapy is more effective and more costly. The ratio of the potential threshold of «willingness to pay» and the ICUR value visually demonstrates that in terms of cost-effectiveness, the technology of Neurocytin® in combination with standard therapy is within the threshold of willingness to pay from the perspective of the state budget. Based on the budget impact analysis results, it was found that the cost of Scenario 3 (an annual 20% increase in the number of patients prescribed Neurocytin® in combination with standard therapy) will amount to 17.2 billion UAH.
- 24 August 2023
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 62-79
Open AccessPharmacoeconomic analysis of the use of combinations of complex electrolyte compounds with citicoline in the treatment of patients with acute ischemic stroke in Ukraine
Ischemic stroke is a clinical syndrome of rapid development of signs of focal or global loss of brain function that lasts 24 hours or more or leads to death without other (nonvascular) causes. Cerebral stroke is one of the most severe forms of cerebrovascular disease. A significant place in stroke pharmacotherapy is occupied by prescription drugs that increase the preservation of nervous tissue. Citicoline is an essential mediator in phosphatidylcholine biosynthesis, a major component of biological membranes. The study aimed to analyze the cost-effectiveness and budget impact on using of complex electrolyt compounds with citicoline combinations in treatment of patients with acute ischemic stroke in Ukraine. The cost analysis was based on a decision tree model developed for treatment within 28 days after an ischemic stroke, including the likelihood that a patient will need to undergo rehabilitation care in an out-patient or in-patient treatment. The cost of direct expenses was determined based on the results of the course of Neurocytin® in combination with standard therapy, compared to the use of standard therapy alone, which, according to the results of the modelled analysis, is 30 407.10 UAH and 28 171.43 UAH per 1 person, respectively. Due to performing a pharmacoeconomic analysis using the cost-effectiveness method, the cost-utility indicator was calculated, which for treatment with Neurocytin® is 47 142.79 UAH, and for standard therapy – 46 031.74 UAH. The calculated ICUR value is 68 996.36 UAH, which indicates that the technology of Neurocytin® in combination with standard therapy is more effective and more costly. The ratio of the potential threshold of «willingness to pay» and the ICUR value visually demonstrates that in terms of cost-effectiveness, the technology of Neurocytin® in combination with standard therapy is within the threshold of willingness to pay from the perspective of the state budget. Based on the budget impact analysis results, it was found that the cost of Scenario 3 (an annual 20% increase in the number of patients prescribed Neurocytin® in combination with standard therapy) will amount to 17.2 billion UAH.